Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 30  |  Issue : 3  |  Page : 700-705

Evaluation of serum prolactin as a potential tumor marker in hepatocellular carcinoma


1 Internal Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
3 Medical Biochemistry Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
4 Internal Medicine Department, Ministry of Health, Tanta, Gharbia, Egypt

Correspondence Address:
Mohamad A Abouhabal
Tanta, Gharbia, 31741
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.218290

Rights and Permissions

Objectives The aim of this study was to evaluate serum prolactin (PRL) as a potential tumor marker in the detection of hepatocellular carcinoma (HCC). Background HCC ranks fifth among the most prevalent cancers worldwide. In Egypt, the incidence of HCC had been doubling because of hepatitis C viral infection. New serum tumor markers are required for the diagnosis of HCC instead of α-fetoprotein (AFP) (the most widely used marker) due to its poor diagnostic accuracy. Prolactin receptor has been identified in a variety of human tissues, such as the liver. When PRL binds to its receptor, it leads to the activation of Janus kinase 2, a tyrosine kinase that can phosphorylate the STAT (signal transducer and activator of transcription) proteins and subsequently functions in cell proliferation and differentiation. Patients and methods Eighty adult patients were selected for this study. They were categorized as follows: group I, which included 10 healthy controls, age and sex matched; group II, which included 40 patients with cirrhosis; and group III, which included four patients with newly diagnosed HCC in addition to cirrhosis. Routine tests for liver cirrhosis and HCC were carried out. Serum PRL was measured using enzyme-linked immunosorbent assay. Results Serum PRL was significantly elevated in the HCC group when compared with the other two groups. There was a significant difference between single and multiple lesions as regards PRL level in the HCC group; it was higher in cases of multiple lesions. Significant positive correlations were found between PRL on one hand and AFP, aspartate aminotransferase platelet ratio index, and tumor size on the other hand. At a cutoff level of at least 44.5 ng/ml, serum PRL had 92.5% sensitivity, 77.5% specificity, 80.43% positive protective value, and 91.18% negative protective value for the diagnosis of HCC. Conclusion Significantly elevated serum PRL in HCC patients may act as promising and potentially complementary biomarker with AFP. It may offer more effective early detection of HCC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed636    
    Printed5    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal